// App-Quantinova.ai

967 : Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Researchers

Presenter

  • Anna Staniszewska

Principal Investigators

  • Joshua Armenia

  • Matthew King

  • Chrysiis Michaloglou

  • Maneesh Singh

  • Maryann San Martin

  • Zena Wilson

  • Theresa Proia

  • Oona Delpuech

  • Mark O'Connor

  • Elisabetta Leo

  • Viia Valge-Archer

Medical Centers

  • AstraZeneca, Waltham, MA

  • AstraZeneca, Alderley Park, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Natural Killer cells

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Cluster of differentiation 86

  • Cluster of differentiation 8A

Drug/Treatment

  • Interferon

  • Olaparib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved